News

Surgeons must use caution to avoid pitfalls of complicated procedure

A late breaking poster at the event in San Diego presented by Paolo S. Silva, MD, reveals AI algorithms for diabetic retinopathy progression risk estimation.

According to researchers, the new imaging approach reveals changes in retinal microcirculation may indicate brain diseases that involve reduced blood flow.

Kaushal Solanki, PhD, discusses how ophthalmologists can now use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy.

According to researchers, the study is the first to assess associations between pre-diagnostic circulating metabolites and POAG risk in two large independent datasets.

The company noted the FDA clearance also includes its proprietary Real-Time Quality Feedback to improve the gradeability of retinal images and reduce the need for eye dilation, expanding the choice for primary care clinics to screen people with diabetes.

Keratopigmentation technique offers therapeutic and cosmetic applications.

Cigna’s Coverage Policy includes procedures enabled with OMNI® Surgical System technology as medically necessary and covered.

Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.

Surgeons seek best IOL match for patients after cataract surgery.

In a presentation at the American Society for Microbiology’s annual meeting, the oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

Vitrectomy is a tool that can help surgeons curb complications.

In April, the FDA approved an update to the TEPEZZA indication language, specifying its use in all patients with TED regardless of TED activity or duration. Horizon Therapeutics presented its data at the Endocrine Society's 2023 annual meeting in Chicago.

The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.

The study results could help lead to improved understanding of glaucoma and new therapies.

On this episode of the NeuroOp Guru video blog, Andy Lee, MD, and Drew Carey, MD, discuss the use of fluoxetine in patients with visual field loss after suffering a stroke.

The MERIT study found that intraocular corticosteroid treatment remains the most effective therapy for uveitis-related macular edema, and vision gains in participants who received the corticosteroid treatment were very promising.

Eyes implanted with the lens demonstrated greater astigmatic tolerance.

Eyebiotech noted its AMARONE trial will evaluate the safety and preliminary efficacy of intravitreal EYE103.

Results of the Alcon Eye on Cataract Survey highlight misconceptions about cataract surgery, revealing the need to educate the 50+ population on the procedure and treatment options.

Researchers are involved in the development of Eye2Gene, an AI system capable of identifying the genetic cause of IRDs from retinal scans.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

A vitreoretinal surgeon, Hariprasad joined the University of Chicago in 2005, and has been serving as interim chairman since 2020.

Scientists hope to develop of novel AI solutions for the prediction of DPN using corneal OCT images.

SBI-100 is a cannabinoid receptor type 1 (CB1R) agonist administered topically onto the eye to reduce IOP and treat glaucoma.